RxDoctor Payments Data

Andrew Dailey, MD

Nephrology · Louisville, KYNPI 1083709893

Payments from drug & device makers

$1,184in general payments, 2019–2025

Across 50 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • Travere Therapeutics, Inc.$157
  • Otsuka America Pharmaceutical, Inc.$129
  • Baxter Healthcare$121
  • Bayer$108
  • Calliditas Therapeutics US Inc.$89
  • plus $354 from 10 others

What the payments were for

  • Food & beverage$1,15898%
  • Education$262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,184 in reported general payments places this provider in the 50th percentile of 165 nephrology providers in Kentucky.

See all nephrology providers in Kentucky

Medicare billing

Part B allowed, 2024
$372,854
Medicare patients
638
Services billed
5,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol33$17,745
VeltassaPatiromer Calcium Sorbitex13$12,560
JardianceEmpagliflozin13$11,116
Lanthanum Carbonate12$10,959
Bumetanide46$2,482
Hydralazine Hcl68$751
Potassium Chloride20$466
Losartan Potassium66$453
Calcitriol40$430
Hydrochlorothiazide62$355
Amlodipine Besylate77$326
Furosemide64$313
Midodrine Hcl16$269
Tamsulosin Hcl21$225
Klor-Con M20Potassium Chloride18$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$226$17,74533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 165 nephrology providers in Kentucky.

Other nephrology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →